EnGeneIC to Present at BIO CEO & Investor Conference 2015

04 Feb, 2015, 07:03 ET from EnGeneIC, Ltd.

SYDNEY, Feb. 4, 2015 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics and other therapeutic molecules, announced today that the Company is scheduled to present at the BIO CEO & Investor Conference taking place in New York City on February 9-10, 2015.

Dr. Himanshu Brahmbhatt and Dr. Jennifer MacDiarmid, Joint-CEOs of EnGeneIC, will be attending the conference, and Himanshu will provide an overview of the Company's business during a live presentation. Both will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event:


BIO CEO & Investor Conference

Date: 


Monday, February 9, 2015 

Time: 


9:30 a.m. (Eastern Time) 

Location:


Waldorf Astoria, New York, NY

About EnGeneIC, Ltd.
EnGeneIC is an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutic and other therapeutic molecules. The company's lead technology platform, EDV™ utilizes antibody-targeted, bacterially derived, non-living "nanocells" to release high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into targeted tumor cells. In doing so, EDVTM nanocells enable current cancer treatments to be more potent and far less toxic, while also offering a potential new means for treating drug-resistant cancers. EnGeneIC is currently preparing an IND for FDA submission, with plans to launch a Phase1/2a clinical trial in recurrent glioblastoma patients in early 2015. Trials are also in planning stages for non-small cell lung cancer.

For more information please visit www.engeneic.com

About BIO CEO & Investor Conference
The 17th annual BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

For EnGeneIC:
Jennifer MacDiarmid, Ph.D.
Joint-CEO and Director
jmacdiarmid@engeneic.com
+61-2-9420-5833

Anjan Chatterji, MBA, J.D., LL.M
EVP Corporate Development
achatterji@engeneic.com 
+1-917-484-1977

Investor / Media Contacts:
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. / Amy S. Wheeler
+1-212-375-2664 / +1-646-362-5750
jdrumm@tiberend.com / awheeler@tiberend.com

SOURCE EnGeneIC, Ltd.



RELATED LINKS

http://www.engeneic.com